Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025 for SRx Health Solutions, Inc. (formerly Better Choice Company, Inc.). The Company operates as a pet health and wellness business through its subsidiary Halo, Purely for Pets, Inc. A material subsequent event occurred on April 24, 2025, when the Company consummated a business combination with SRx Health Solutions (Canada) Inc., acquiring a specialty pharmacy network. The financial statements presented reflect the Company's operations prior to this merger.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $7.16 million | $7.90 million |
| Gross Profit | $2.38 million | $2.61 million |
| Gross Margin | 33% | 33% |
| Operating Loss | $(1.09) million | $(2.47) million |
| Net Loss | $(0.96) million | $(2.83) million |
| Cash and Equivalents | $1.14 million | $3.07 million (Dec 31, 2024) |
| Operating Cash Flow | $0.38 million | $(1.01) million |
| Debt (Wintrust Facility) | $1.23 million | $2.41 million (Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 9% year-over-year, primarily due to the strategic exit of the Direct-to-Consumer (DTC) channel in June 2024. However, International sales grew significantly, rising from 36% to 56% of total revenue.
- Improved Profitability: The Net Loss improved by 66% to $0.96 million, driven by a 32% reduction in operating expenses and the elimination of interest expense from the Alphia Term Loan following a settlement.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses dropped $1.61 million. Key drivers included reduced marketing spend, lower employee compensation due to headcount reductions, and the cessation of DTC freight costs.
- Debt Settlement: The Company settled litigation with Alphia Inc., resulting in the forgiveness of a $5.0 million term loan and $2.6 million in accounts payable, eliminating a significant debt burden.
Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern for the next 12 months due to historical losses and an accumulated deficit of $322.5 million. Additional capital or financing is required to maintain operations.
- Listing Compliance: The Company is subject to NYSE American delisting risks due to non-compliance with stockholders' equity and profitability requirements. A compliance plan has been accepted, but failure to meet standards by October 24, 2025, could result in delisting.
- Subsequent Events:
- Merger: Completed the acquisition of SRx Health (Canada) on April 24, 2025, diversifying into specialty pharmacy.
- Asset Sale: Sold the Asian business in April 2025 for $8.1 million (including $6.5 million cash and a 5-year royalty agreement).
- Internal Controls: The Company disclosed material weaknesses in internal controls over financial reporting, specifically regarding revenue recognition and IT general controls (access, change management, cybersecurity).
Investor Verification Checklist
- Verify the status of the NYSE American compliance plan and the timeline for regaining full listing standards.
- Confirm the integration progress and financial impact of the newly acquired SRx Health (Canada) specialty pharmacy business.
- Assess the sufficiency of current cash reserves ($1.14 million) against the stated need for additional capital to address the going concern warning.
- Review the details of the Asian business sale and the enforceability of the future royalty payments.
- Monitor the remediation of material weaknesses in internal controls over revenue recognition and IT systems.